in the early phases of PD. 9 The recognition that specific NMSs, such as olfactory dysfunction, dysautonomia, mood and sleep disorders, occur in the premotor phase of PD has given rise to the possibility of early diagnosis of PD. Considering that DIP is caused by selective antagonism at striatal dopamine receptors, it may not be accompanied by the PD-specific NMSs that result from neurodegeneration of the brain stem nucleus. 10 In the present study, we aimed to distinguish between DIP and drugnaïve PD in the early stages by NMSs using Non-Motor Symptoms Scale (NMSS) at initial stage in the patients with parkinsonism.
PATIENTS AND METHODS

Patients
We prospectively enrolled 28 patients with DIP and 35 patients with drug-naïve PD in the early stages. Eligible patients met the following clinical criteria for DIP 11 : (1)The presence of at least two of the four cardinal signs of PD (tremor, rigidity, bradykinesia, and impaired postural reflexes); (2) absence of a personal history of extrapyramidal disorders before treatment with an offending drug; and (3) onset of symptoms during the course of treatment with an offending drug. In addition, positron emission tomography (PET) using 18 F-N-(3-fluoropropyl)-2beta-carbonethoxy-3beta-(4-iodophenyl) nortropane (FP-CIT) was used to improve the diagnostic accuracy of DIP. We excluded patients suffering from severe medical diseases or psychosis. A clinical diagnosis of PD was made according to the UK Brain Bank criteria. 12 To exclude the influence of levodopa on NMSs, we only included patients who were drug-naïve to anti-parkinsonian medications. All of the patients with PD and DIP underwent brain magnetic resonance imaging to exclude other possible causes of parkinsonism such as vascular lesion or tumors. We also enrolled 32 controls with no history of medical or neurological diseases and medications. This study was approved by Institutional Review Board of the Samsung Medical Center, Seoul, Korea and each patient provided informed consent to participate.
Assessment
We obtained demographic and historical information from all patients, including age, gender, causative drug (DIP patients only), underlying disease, detailed medical and drug histories, and time from symptom onset to diagnosis of parkinsonism. In addition, a complete neurological examination, including the motor portion of the Unified Parkinson's Disease Rating Scale (UPDRS Part III) and Hoehn and Yahr (H&Y) stage, was performed. To measure NMSs, we used NMSS, 13 a widely-used scale of NMSs identification consisting of cardiovascular, sleep/fatigue, mood/cognition, perceptual problems, attention/ memory, gastrointestinal, urinary, sexual function, and miscellaneous domains.
Statistical analysis
The statistical analysis was performed with SPSS version 18.0 (Chicago, IL, USA). Kruskal-Wallis tests with Bonferroni post hoc testing were used to compare NMSS scores between the DIP, PD, and control groups. To determine the correlation between each measurement and the diagnosis of DIP or PD while controlling for age and gender, partial Spearman correlation analyses were used. The significance threshold was set to 0.05. Nonparametric tests and one-way analysis of variance (ANOVA) were used to compare demographic variables. 
RESULTS
Patient characteristics
Among patients with DIP, levosulpiride (57%) was the most common offending drug, followed by flunarizine (21.4%) ( Table  1 ). Most patients with DIP showed relatively subacute onset after exposure of offending drug and symmetric motor features and seven patients showed additional features such as oromandibular dyskinesia. Twenty of 28 patients (71.4%) with DIP were evaluated with FP-CIT PET. Three of these patients had reduced FP-CIT binding in the posterior putamen, and they were excluded from further analysis because they were considered as DIP with subclinical PD. Eight patients who did not undergo FP-CIT PET demonstrated an improvement in parkinsonian symptoms, although not necessarily completely, after discontinuing use of the offending drugs during follow-up for more than three months without anti-parkinsonian medication. groups. The patients in the DIP group were older and had a higher female-to-male ratio than patients in the PD group. The duration of parkinsonism from symptom onset to time to diagnosis was significantly shorter in the DIP group than the PD group. The motor function (UPDRS part III, H & Y stage) was worse in DIP patients than PD patients; however, the difference of UPDRS part III was not significant.
Comparisons of each domain and item of the NMSS
Total NMSS score was significantly higher in the PD group than the DIP group. When each of the nine NMSS domains were compared among the three groups in post hoc analyses, the scores for the cardiovascular, sleep/fatigue, urinary, sexual function, and miscellaneous domains were higher in the PD group than the DIP group. (Figure) Most of the individual items of the NMSS were significantly different among the three groups ( Table 3 ). The post hoc analyses showed that the scores for sleep disturbance including daytime sleep, restless legs; concentration; urinary symptoms including urgency, frequency, and nocturia; sexual dysfunction including interest in sex and problems having sex; miscellaneous symptoms including pain, taste and smell were significantly higher in the PD group than the DIP group. Table 4 depicts the results of the correlation analysis that controlled for age and gender. The correlation of measures related to motor function (higher UPDRS part III and H & Y stage) with DIP was low to moderate (r s = 0.270 -0.417). For each individual item of the NMSS, urgency, frequency, nocturia, daytime sleep, concentration, taste or smell were moderately associated with PD (r s = 0.328 -0.481). Only a weak association was found between restless legs and PD (r s = 0.264). Significant correlations were not found for the remaining items.
Correlation analysis
DISCUSSION
To our knowledge, this is the first study to compare NMSs between patients with DIP and PD using the NMSS. To rule out the possibility of a medication effect, 14 we only included antiparkinsonian drug-naïve patients. We found that the total NMSS scores were significantly greater in patients with PD than with DIP, and the scores for certain symptoms, such as urinary symptoms, including frequency, urgency, and nocturia; sleep disturbances, including excessive daytime sleepiness (EDS) and restless leg syndrome (RLS); attention deficit; and hyposmia were significantly correlated with PD, suggesting that NMSs, especially the specific ones listed above, might be useful for differentiating between patients with PD and those with DIP in the early stages. Most antipsychotic agents work by inhibiting transmission in the mesocorticolimbic system, and they simultaneously cause extrapyramidal symptoms by inhibiting transmission in the nigrostriatal system. 15 Levosulpiride 3 and the newer calciumchannel blockers, such as flunarizine and cinnarizine, 5 also cause parkinsonism by inhibiting the dopamine D2 receptor. These drugs produce a functional dopaminergic-deficient state and hence cause clinical symptoms that mimic PD. According to Braak et al, 10 PD may be initiated by the deposition of Lewy bodies in involved nerve cells in the caudal brainstem, and this pathological process has an ascending temporal sequence that develops to affect other parts of the brain, causing various NMSs. Before the emergence of the traditional motor triad of tremor, rigidity, and bradykinesia caused by neurodegeneration in the substantia nigra and other deep nuclei of the midbrain and forebrain -so-called "premotor phase", olfactory dysfunction, dysautonomia, sleep and mood disturbances might be preceded by affecting olfactory bulb or brainstem nuclei such as raphe nucleus, locus coeruleus, pedunculopontine nucleus and dorsal motor nucleus of vagus. 9, 16 Considering that DIP occurs through selective antagonism of the dopaminergic pathway, NMSs specific to PD that are caused by a degenerative process in the brain stem may be uncommon in DIP.
To date, possible pre-motor symptoms for PD of which there is strong or suggestive evidence include olfactory deficit; constipation; sleep disorders, such as EDS and rapid eye movement sleep behavior disorder (RBD); and depression. 9, [16] [17] [18] Recent studies that investigated the whole spectrum of NMSs in PD also showed a high frequency of certain NMSs in patients with PD, even in the early stages. 19, 20 We found a significant correlation between PD and urinary frequency, urgency, and nocturia; EDS and RLS; attention deficit; and hyposmia, results that are generally consistent with those of previous studies. Since the brain stem structures responsible for the above symptoms of PD are already involved in Braak stages 2-3, 10 these problems may be part of the prodromal phase and could be helpful to recognize PD in the early stage compared with DIP. Gastrointestinal problems, one of the possible NMSs with strong evidence, were not significantly different between patients with PD and DIP in this study. Considering that the most common causative drug for DIP was levosulpiride, most patients with DIP may have had underlying gastrointestinal problems.
The cardiovascular, perceptual, sexual, mood/cognition, and attention/memory domains (with the exception of concentration) failed to show significant correlations with PD in this study. Although the prevalence of these symptoms is high in patients with PD, [21] [22] [23] [24] [25] these diagnoses are also common in the general population, so they have low sensitivity and specificity in predicting subsequent Parkinson's disease. 26 Since we only included drug-naïve patients in the early stages of PD, this may explain why the frequencies of complaints related to the cardiovascular system and perceptual problems were generally low; these symptoms are uncommon in early PD 9 but become more frequent as the disease progresses. 27 The patients with DIP demonstrated poorer motor function and had a shorter disease duration than those with PD, so the relatively subacute onset and more severe parkinsonism of the DIP patients might have influenced the results on mood. Furthermore, four patients had rs = partial correlation coefficient adjusted by age and gender. Our study has several limitations. First, the NMSS does not assess RBD, which is a well-known premotor symptom with strong pathological support. Hence, we could not investigate all possible premotor symptoms in this study. Second, we evaluated a relatively small sample of patients at a single medical facility, so our findings may not be representative of all patients with DIP. Third, we could not exclude the possibility that patients with subclinical PD were included in the DIP group. However, twenty of 28 patients with DIP had their diagnosis confirmed by FP-CIP PET scan, and clinical phenotype of patients with DIP showed subacute onset and symmetric motor symptoms, and combined with oromandibular dyskinesia. Furthermore, we observed an improvement in parkinsonism after discontinuing the offending drugs during follow-up of more than three months and excluded the patient who showed reduced FP-CIT binding in the posterior putamen from analysis. Fourth, demographics such as age and gender are significantly different between the DIP and PD group and this might affect the results. However, there were previous reports that showed no significant differences in NMSs by gender. 20 Furthermore, we analyzed data with adjustment of different demographic factors including age and gender.
The present study is the first to use NMSs to distinguish between DIP and PD. The NMSS is simpler to administer and less invasive and expensive than DAT imaging. We suggest that NMSs, particularly urinary symptoms, hyposmia, EDS, RLS, and attention deficit, may help physicians distinguish between patients with DIP and patients with PD in the early stages. A careful assessment of NMSs may not only assist differentiation between DIP and PD, but also help ensure that patients with parkinsonism receive appropriate and timely treatment.
